Quantcast

Latest Lundbeck Stories

2014-07-24 23:02:33

New comprehensive report “Memantine - Comprehensive patent search” elaborated by Ark Patent Intelligence is now available at MarketPublishers.com. London, UK (PRWEB) July 24, 2014 Memantine was initially developed by Merz to treat Alzheimer’s disease (AD) and was first marketed in Germany under the brand name Akatinol; it was later licensed to Lundbeck Ltd. in Europe and other nations as Ebixa and in the USA to Forest Labs as Namenda. Lundbeck reported the sales of Ebixa of USD 420...

2014-07-21 12:25:38

Blockbuster Status Awaits Novel DMTs and Lundbeck/Otsuka's Emerging Symptomatic Agent Lu-AE58054, According to Findings from Decision Resources Group BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, owing largely to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment. In 2023, these novel...

2014-07-02 23:03:21

MarketReportsOnline.com adds "Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis" report to its research store. Dallas, Texas (PRWEB) July 02, 2014 Alzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s disease, it still remains a significant area of unmet medical need. Clinical success has...

2014-06-23 12:29:42

Data Highlight Physician and Payer Receptivity to Emerging Agents for Treatment-Resistant Depression, According to Findings from Decision Resources Group BURLINGTON, Mass., June 23, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant depression (TRD) and would prescribe Otsuka/Lundbeck's emerging atypical antipsychotic brexpiprazole to a mean 12 percent of their drug-treated...

2014-06-17 08:30:31

Takeda and Lundbeck Announce Results at American Society of Clinical Psychopharmacology Annual Meeting HOLLYWOOD, Fla., June 17, 2014 /PRNewswire/ -- Takeda Pharmaceuticals Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will present results about sexual functioning from a head-to-head study of Brintellix(®) (vortioxetine) vs. escitalopram in patients with well treated major depressive disorder (MDD) experiencing treatment-emergent sexual...

2014-06-16 08:27:34

Takeda and Lundbeck to Present Late-breaker at International College of Neuropsychopharmacology World Congress VANCOUVER, British Columbia, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated the effect of Brintellix 10-20 mg/d on aspects of cognitive function, using an objective neuropsychological test (the Digit Symbol Substitution Test or DSST) associated with executive...

2014-06-12 23:04:38

ReportsnReports.com adds “PharmaPoint Major Depressive Disorder - Current and Future Players” to its store. Order a purchase copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=288099. Dallas, Texas (PRWEB) June 12, 2014 “PharmaPoint: Major Depressive Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report...

2014-05-05 08:28:42

MONTREAL, May 5, 2014 /CNW/ - Canadians living with schizophrenia now have a new option to help treat their disease. Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. announce today that ABILIFY MAINTENA(TM) (aripiprazole for prolonged release injectable suspension), indicated for the maintenance treatment of schizophrenia in stabilized adult patients, is now commercially available for use in Canada. ABILIFY MAINTENA(TM) is the first product in Canada from the global...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related